Agilent Technologies Q3 revenue was $1.01 billion
Third-quarter revenue was $1.01 billion, up 1 percent, up 9 percent on a core basis, compared with one year ago.
Third-quarter GAAP income from continuing operations was $105 million, or $0.31 per share. Last year's third-quarter GAAP income from continuing operations was $63 million, or $0.19 per share.
During the third quarter, Agilent had intangible amortization of $38 million, transformation costs of $12 million, acquisition and integration costs of $4 million, and a tax benefit of $14 million.
Excluding these items, and $2 million of other costs, Agilent reported third-quarter adjusted income from continuing operations of $147 million, or $0.44 per share.
Third-quarter revenue of $511 million from Agilent's Life Sciences and Applied Markets Group (LSAG) grew 1 percent year over year (up 9 percent on a core basis), driven by strong performance in pharma, environmental and forensics markets. LSAG's Q3 operating margin was 18.7 percent.
Third-quarter revenue of $336 million from the Agilent CrossLab Group (ACG) was flat year over year (up 8 percent on a core basis), led by continued strong acceptance of the company's CrossLab services and consumables offerings. ACG's operating margin was 22.6 percent in the quarter.
Third-quarter revenue of $167 million from Agilent's Diagnostics and Genomics Group (DGG) was flat year over year (up 10 percent on a core basis), with continued strong growth across all its businesses. DGG's operating margin for the quarter was 16.8 percent.
Agilent expects fourth-quarter 2015 revenue in the range of $1.03 billion to $1.05 billion. Fourth-quarter non-GAAP earnings are expected to be in the range of $0.45 to $0.49 per share.
For fiscal year 2015, Agilent expects revenue of $4.03 billion to $4.05 billion and non-GAAP earnings of $1.68 to $1.72 per share. The guidance is based on July 31, 2015, exchange rates. ■